



180 order

DBL

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

4-21-92
(Date of Deposit)

By

David Schaper

RECEIVED

MAY 06 1992

APPLICATION DIVISION
CGNE-69-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of
Thompson, et al.

Examiner: P. Rhodes

Art Unit: 1804 ✓

Serial No. 07/762,762

Filed: September 16, 1991

SEQUENCE LISTING,
COMPUTER READABLE FORM,
AND VERIFIED STATEMENT
UNDER CFR 37 1.821-1.825

For: PLANT DESATURASES -
COMPOSITIONS AND USES

Commissioner of Patents and Trademarks
Box PCT
Washington, DC 20231

RECEIVED

APR 29 1992

GROUP 180

Dear Sir:

In response to the Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on March 27, 1992, provided herein are a formatted Sequence Listing and a copy of the Sequence listing on computer readable form as required by 37 CFR 1.821 through 1.825.

The content of the paper and computer readable forms are the same (§ 1.821(f)).

This submission does not include new matter (§ 1.821(g)).

A conditional petition for an Extension of Time is requested to provide for the timely filing if an extension of time is required after all papers filed with this transmittal have been considered.

Furthermore, the Commissioner is hereby authorized to charge any required fees, or credit any overpayment of any fees relating to the attached document to Deposit Account No. 03-0173.

Respectfully submitted,

Donna E. Scherer

Donna E. Scherer
Reg. No. 34,719

CALGENE, INC.
1920 Fifth Street
Davis, CA 95616
(916) 753-6313

enclosure: Sequence Listing
Computer Readable Form



Applicant's copy
#10

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows:

- ☒ 1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached.
- ☐ 2. This application does not conform exclusively to the requirements of §§ 1.821 through 1.825. The non-conforming material should be deleted. § 1.821(b).
- ☐ 3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c).
- ☐ 4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows:
 - ☐ a. The sequence data does not comply with the symbol requirements of paragraphs (b) through (p) of § 1.822. Specifically: RECEIVED
APR 27 1992
GROUP 180
 - ☐ b. The "Sequence Listing" does not comply with the location requirements of paragraph (a) of § 1.823.
 - ☐ c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically: _____
 - ☐ d. Other: _____
- ☐ 5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d).
- ☐ 6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e).
- ☐ 7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically: _____
- ☐ 8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f).
- ☐ 9. The amendment to or replacement of the paper and/or computer readable copies of the "Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).
- ☐ 10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that originally filed. § 1.825(d). Specifically: _____
- ☒ 11. Other: New sequence data in Figures 3, 4A, 4B, 4C, 5 and 8 are not found in the
parent applications; this sequence rules apply to this CIP application. (11/4 02, 29)
APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH
TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the above require-
ments will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of
time may be obtained by filing a petition accompanied by the extension fee under the provisions of
37 CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A
copy of this notice MUST be returned with your response.

☐ For: Manager, Application Processing Division
(703) 308-1202 or 308- _____

☒ P. Rhodes
Examining Group 1804
(703) 308- 3224